Metprogen Profile
Key Indicators
- Authorised Capital ₹ 0.30 M
as on 09-12-2024
- Paid Up Capital ₹ 0.10 M
as on 09-12-2024
- Company Age 7 Year, 3 Months
- Last Filing with ROC 31 Mar 2021
- Revenue %
(FY 2021)
- Profit -42.86%
(FY 2021)
- Ebitda -42.86%
(FY 2021)
- Net Worth -5.46%
(FY 2021)
- Total Assets %
(FY 2021)
About Metprogen
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.30 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Apparsundram Rajanikanth, Thirunavukarasu Thavendravakkam, and Rajnikanth Preeti serve as directors at the Company.
- CIN/LLPIN
U24100TN2017PTC118688
- Company No.
118688
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Sep 2017
- Date of AGM
24 Sep 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Tiruvallur, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Metprogen?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Apparsundram Rajanikanth  | Director | 04-Mar-2020 | Current |
| Thirunavukarasu Thavendravakkam | Director | 19-Sep-2017 | Current |
| Rajnikanth Preeti | Director | 19-Sep-2017 | Current |
Financial Performance and Corporate Structure Insights of Metprogen.
Metprogen Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 42.86% decrease in profit. The company's net worth dipped by a decrease of 5.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Metprogen?
Unlock access to Metprogen's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Remedium Therapeutics Private LimitedActive 4 years 4 monthsApparsundram Rajanikanth is a mutual person
Vclinbio Pharmaceuticals Private LimitedActive 7 years 10 monthsApparsundram Rajanikanth is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Metprogen?
Unlock and access historical data on people associated with Metprogen, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Metprogen, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Metprogen's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
